Dedicated breast PET and MRI for characterization of breast cancer and its response to therapy
Dedicated breast PET and MRI for characterization of breast cancer and its response to therapy
批准号:
10335144
负责人:
Jorge Alamo
金额:
$57.82万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-02-01 至 2024-07-31
关键词:
AdoptedAftercareAlgorithmsBlood VesselsBreastBreast DiseasesBreast Magnetic Resonance ImagingCancer BurdenCancer CenterCharacteristicsClinicalClinical ManagementClinical Trials DesignCompanionsComputer softwareDataDevelopmentDiseaseDoseEarly treatmentEnrollmentEvaluationGenomicsGoalsImageImage AnalysisIn complete remissionIndustrializationInterventionInvestigationLeadLesionLogistic RegressionsMagnetic Resonance ImagingMalignant NeoplasmsMammographyMeasurementMetabolicMetastatic breast cancerMolecularMonitorMorphologyNeoadjuvant TherapyNonmetastaticOutcomeOutputPathologicPatientsPerformancePhase II Clinical TrialsPositioning AttributePositron-Emission TomographyPrediction of Response to TherapyProspective StudiesResearch PersonnelResidual CancersResolutionRoleScanningSelection for TreatmentsSignal TransductionSoftware ToolsStandardizationSystemTechnologyTestingTextureTimeTracerTranslatingTranslationsTumor BiologyTumor VolumeWorkattenuationbasebiological heterogeneitybiomarker performancecancer biomarkerscancer subtypeschemotherapycontrast enhancedcostcost effectivecytotoxicityeffective interventioneffective therapyexperienceimage processingimage registrationimaging biomarkerimprovedin vivo imaging systemindustry partnerinterestmalignant breast neoplasmnovelnovel therapeuticsperformance testspredicting responsepredictive modelingpredictive testprognostic valueradiologistradiomicsradiotracerresearch clinical testingresponseserial imagingsoftware developmenttooltreatment responsetumortumor metabolismuptakeuser-friendly
中文摘要
项目总结/摘要
这个学术-工业伙伴关系(AIP)项目的目标是展示专用
乳腺正电子发射断层扫描(dbPET)用于表征原发性乳腺癌及其对
新辅助化疗(NAC)。动态增强磁共振成像(DCE-MRI)
描述了肿瘤形态学和血管分布对NAC的反应,dbPET提供了补充
关于肿瘤代谢的信息,可以有力地预测治疗过程中早期的治疗反应。
疗法我们把这个项目的重点放在OncoVision的MAMMI dbPET上,因为它提供了关键的组合,
具有高空间分辨率和灵敏度,可以实现代谢变化的准确肿瘤内映射,
只有全身PET放射性示踪剂剂量的一半的小病变。重要的是,这个新系统可以扩展PET
该技术在早期(转移前)乳腺癌环境中在经济上和临床上都是可行的。作为
I-SPY 2试验的成像负责人(PI:Nola Hylton),该临床试验旨在确定新的治疗方法
对于乳腺癌,我们处于一个独特的位置,可以整合和测试FDG-dbPET的性能,作为早期诊断乳腺癌的方法。
治疗反应的标志物。作为学术-工业合作伙伴,UCSF和OncoVision将共同努力,
开发一种用户友好和具有成本效益的dbPET技术,可以很容易地应用于临床
大多数乳腺癌中心的工作流程。在具体目标1中,我们将开发软件功能,
dbPET图像配准和量化,以准确量化治疗的纵向变化。在
具体目标2,我们将采集I-SPY 2患者子集的治疗前和治疗后FDG-dbPET图像
并临床评估肿瘤代谢度量(即,优化的标准化摄取值,SUV),
dbPET可以作为病理完全缓解的早期预测因子-与之相比,以及与之组合
与来自DCE-MRI的功能性肿瘤体积(FTV)度量。我们将测试
dbPET SUV和组合SUV+FTV使用逻辑回归预测模型。我们亦会探讨
dbPET和DCE-MRI放射组学特征与乳腺癌生物标志物的相关性,
具有预后价值的影像学特征。此外,我们的前瞻性研究的dbPET数据将用于
评估在具体目标1中开发的软件功能。我们期待着这一工作的圆满完成。
AIP项目,使MAMMI dbPET能够用于常规乳腺癌管理,并制作一套
与肿瘤生物学相关的成像生物标志物及其响应于治疗的变化。
英文摘要
PROJECT SUMMARY/ABSTRACT
The objective of this academic-industrial partnership (AIP) project is to demonstrate the utility of dedicated
breast positron emission tomography (dbPET) for characterizing primary breast cancers and their response to
neoadjuvant chemotherapy (NAC). While dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)
depicts changes in tumor morphology and vascularity in response to NAC, dbPET provides complementary
information about tumor metabolism that can powerfully predict treatment response earlier in the course of
therapy. We focus this project on MAMMI dbPET by OncoVision because it provides the crucial combination
of high spatial resolution and sensitivity that can enable accurate intratumoral mapping of metabolic changes in
small lesions with only half the radiotracer dose of whole-body PET. Importantly, this new system scales PET
technology to be both economically and clinically feasible in the early (pre-metastatic) breast cancer setting. As
the imaging lead (PI: Nola Hylton) of the I-SPY 2 TRIAL, a clinical trial designed to identify novel therapeutics
for breast cancer, we are in a unique position to integrate and test the performance of FDG-dbPET as an early
marker for treatment response. As academic-industrial partners, UCSF and OncoVision will work together to
develop a user-friendly and cost-effective dbPET technology that can be easily adopted into the clinical
workflow of most breast cancer centers. In Specific Aim 1, we will develop software capabilities to standardize
dbPET image registration and quantification to accurately quantify longitudinal changes with treatment. In
Specific Aim 2, we will acquire pre- and post-treatment FDG-dbPET images of a subset of I-SPY 2 patients
and clinically evaluate whether tumor metabolic metrics (i.e., optimized standardized uptake values, SUV) from
dbPET can act as early predictors of pathologic complete response — in comparison to, and in combination
with, the functional tumor volume (FTV) metric from DCE-MRI. We will test the biomarker performance of
dbPET SUV and combined SUV+FTV using logistic regression predictive models. We will also explore the
association of dbPET and DCE-MRI radiomic features with breast cancer biomarkers in order to identify
imaging features with prognostic value. In addition, our prospective study’s dbPET data will be used to
evaluate the software capabilities developed in Specific Aim 1. We expect the successful completion of this
AIP project to enable the use of MAMMI dbPET in routine breast cancer management and to produce a set of
imaging biomarkers relevant to tumor biology and its change in response to treatment.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金